Prussian Blue Insoluble Capsules
Generic Name: prussian blue insoluble capsules
Brand Names:
Radiogardase
11 DESCRIPTION Radiogardase (prussian blue insoluble) is a decorporation agent for oral use. Radiogardase capsules contain insoluble ferric hexacyanoferrate(II), with an empirical formula of Fe 4 [Fe(CN) 6 ] 3 and a molecular weight of 859.3 Daltons. It is supplied as 0.5 gram of blue powder in gelatin capsules with 0 – 38 mg of microcrystalline cellulose. The dark blue capsule is imprinted with the light blue inscription: PB.
Overview
11 DESCRIPTION Radiogardase (prussian blue insoluble) is a decorporation agent for oral use. Radiogardase capsules contain insoluble ferric hexacyanoferrate(II), with an empirical formula of Fe 4 [Fe(CN) 6 ] 3 and a molecular weight of 859.3 Daltons. It is supplied as 0.5 gram of blue powder in gelatin capsules with 0 – 38 mg of microcrystalline cellulose. The dark blue capsule is imprinted with the light blue inscription: PB.
Uses
1 INDICATIONS AND USAGE Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium, in order to increase their rates of elimination. Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. ( 1 )
Dosage
2 DOSAGE AND ADMINISTRATION Adults and Adolescents: 3 grams orally three times a day ( 2.3 ) Pediatrics (2 – 12 years): 1 gram orally three times a day ( 2.3 ) Administer as soon as possible after internal contamination with cesium or thallium is suspected ( 2.1 ) 2.1 Important Administration Instructions Obtain quantitative baseline of the internalized contamination by radioactive cesium (137Cs) and/or thallium by appropriate whole-body counting and/or by bioassay (e.g., biodosimetry), or feces/urine samples, whenever possible prior to Radiogardase treatment. Initiate treatment with Radiogardase as soon as possible after contamination is suspected. Even when delayed, treatment with Radiogardase is effective and should not be withheld.
Side Effects
6 ADVERSE REACTIONS Constipation was reported in 10 (24%) of 42 patients treated with Radiogardase. Severity of constipation was mild in 7 patients and moderate in 3 patients [see Warnings and Precautions (5.2) ]. Most common adverse reaction (incidence >24%) was constipation ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact info@heyl-berlin.de, Fax +49 30 817 4049 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Interactions
7 DRUG INTERACTIONS Based on animal data, co-administration of Radiogardase with other decorporation agents does not affect the efficacy of Radiogardase for treatment of internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium.
Warnings
5 WARNINGS AND PRECAUTIONS Increased radiation absorbed dose to gastrointestinal mucosa : Monitor for decreased gastrointestinal motility ( 5.1 ) Constipation : Monitor and treat ( 5.2 ) Electrolyte abnormalities : Monitor serum electrolytes during treatment ( 5.3 ) Blue discoloration of stool, oral mucosa and dentition ( 5.4 ) 5.1 Increased Radiation Absorbed Dose to Gastrointestinal Mucosa Radiogardase can decrease gastrointestinal motility, thus slowing the transit time of radioactivity in the gastrointestinal tract. The slowed transit time can increase the radiation absorbed dose to the gastrointestinal mucosa. 5.2 Constipation Radiogardase can cause constipation. Monitor and treat for signs and symptoms of constipation. 4 CONTRAINDICATIONS None None ( 4 )
Pregnancy
8.1 Pregnancy Pregnancy Category C It is not known whether Radiogardase can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Animal reproduction studies have not been conducted with prussian blue insoluble. However, since Radiogardase is not absorbed from the gastrointestinal tract, effects on the fetus are not expected. Radioactive cesium ( 137 Cs) crosses the human placenta. One patient, contaminated with 0.005 mCi 137 Cs during her 4 th month of pregnancy, was not treated with Radiogardase.
Storage
16 HOW SUPPLIED/STORAGE AND HANDLING Radiogardase is supplied as gelatin capsules containing 0.5 grams of prussian blue insoluble for oral administration. The dark blue capsule is imprinted with the light blue inscription: PB. It is packaged in white plastic containers with a child-resistant tamper-evident closure. Each container contains 36 capsules.
Frequently Asked Questions
What is Prussian Blue Insoluble Capsules used for?▼
1 INDICATIONS AND USAGE Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium, in order to increase their rates of elimination. Radiogardase is indicated for treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination. ( 1 )
What are the side effects of Prussian Blue Insoluble Capsules?▼
6 ADVERSE REACTIONS Constipation was reported in 10 (24%) of 42 patients treated with Radiogardase. Severity of constipation was mild in 7 patients and moderate in 3 patients [see Warnings and Precautions (5.2) ]. Most common adverse reaction (incidence >24%) was constipation ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact info@heyl-berlin.de, Fax +49 30 817 4049 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Can I take Prussian Blue Insoluble Capsules during pregnancy?▼
8.1 Pregnancy Pregnancy Category C It is not known whether Radiogardase can cause fetal harm when administered to a pregnant woman or if it can affect reproduction capacity. Animal reproduction studies have not been conducted with prussian blue insoluble. However, since Radiogardase is not absorbed from the gastrointestinal tract, effects on the fetus are not expected. Radioactive cesium ( 137 Cs) crosses the human placenta. One patient, contaminated with 0.005 mCi 137 Cs during her 4 th month of pregnancy, was not treated with Radiogardase.
What are the important warnings for Prussian Blue Insoluble Capsules?▼
5 WARNINGS AND PRECAUTIONS Increased radiation absorbed dose to gastrointestinal mucosa : Monitor for decreased gastrointestinal motility ( 5.1 ) Constipation : Monitor and treat ( 5.2 ) Electrolyte abnormalities : Monitor serum electrolytes during treatment ( 5.3 ) Blue discoloration of stool, oral mucosa and dentition ( 5.4 ) 5.1 Increased Radiation Absorbed Dose to Gastrointestinal Mucosa Radiogardase can decrease gastrointestinal motility, thus slowing the transit time of radioactivity in the gastrointestinal tract. The slowed transit time can increase the radiation absorbed dose to the gastrointestinal mucosa. 5.2 Constipation Radiogardase can cause constipation. Monitor and treat for signs and symptoms of constipation. 4 CONTRAINDICATIONS None None ( 4 )
Related Medications
Echinacea (angustifolia), Lomatium Dissectum, Nasturtium Aquaticum, Tabebuia Impetiginosa, Hydrastis Canadensis, Iodium, Adrenalinum, Argentum Metallicum, Thymus (suis), Thyroidinum (suis), Phosphoricum Acidum, Candida Albicans, Lycopodium Clavatum, Pulsatilla (vulgaris), Sepia
echinacea (angustifolia), lomatium dissectum, nasturtium aquaticum, tabebuia impetiginosa, hydrastis canadensis, iodium, adrenalinum, argentum metallicum, thymus (suis), thyroidinum (suis), phosphoricum acidum, candida albicans, lycopodium clavatum, pulsatilla (vulgaris), sepia
Non-Standardized Fungal Allergenic Extract [EPC]
PURPOSE: Adrenalinum – lung congestion,** Argentum Metallicum – cold symptoms,** Candida Albicans - indigestion,** Echinacea – sore throat,** Hydrastis Canadensis – abdominal gas,** Iodium - fatigue,** Lomatium Dissectum – mucus congestion,** Lycopodium Clavatum - bloating,** Nasturtium Aquaticum - swelling,** Tabebuia Impetiginosa – occasional diarrhea,** Thymus - fatigue,** Thyroidinum – abdominal pain,** Phosphoricum Acidum – dry mouth,** Pulsatilla – abdominal cramps,** Sepia – constipation*
Propylene Glycol, Glyceryl Stearate Se, Humulus Lupulus (hops) Cone Extract
propylene glycol, glyceryl stearate se, humulus lupulus (hops) cone extract
Non-Standardized Chemical Allergen [EPC]
Regul Oil Cleansing Cream purpose
Filgrastim-txid
filgrastim-txid
Leukocyte Growth Factor [EPC]
11 DESCRIPTION Filgrastim-txid, a leukocyte growth factor, is a 175 amino acid human granulocyte colony-stimulating factor (G-CSF) manufactured by recombinant DNA technology. Filgrastim-txid is produced by Escherichia coli ( E. coli ) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. Filgrastim-txid has a molecular weight of 18‚800 daltons.
Medical Disclaimer
This drug information is for educational purposes only and should not replace professional medical advice. Drug information is sourced from the FDA National Drug Code Directory and Structured Product Labeling. Always consult with a healthcare provider before starting, stopping, or changing any medication.